The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 ...

Nat Clin Pract Endocrinol Metab. 2008;4(11):627-634. Adipocytes are morphologically unique, since lipid droplets occupy a large part of the intracellular region and the nucleus and cytosome are ...

CBL-514, a potentially first-in-class small-molecule drug, is a lipolysis injection that can induce adipocyte apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas without ...